Daniel D. Von Hoff
Translational Genomics Research Institute · 1,523 works · 70,855 citations · h-index 108
Top works
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
- Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction.
- Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- Hypersensitivity reactions from taxol.
- Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
- Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
- A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
- Aberrant Subcellular Localization of BRCA1 in Breast Cancer
- Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
- Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy
- Daunomycin-induced cardiotoxicity in children and adults
- Gemcitabine Plus nab -Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- Prospective clinical trial of a human tumor cloning system.
- ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
- Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile
- Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers